Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1905 in chronic rhinosinusitis with nasal polyps
NCT07132827Phase 3Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Aug 2025
- Primary completion
- Apr 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of SHR-1905 in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Hengrui Therapeutics. Started Aug 2025; status: recruiting.
02
Drugs
SHR-1905
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT07132827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07132827.